K+N to strengthen European pharma market with 45 new trailers by year end
K N is investing in its European pharma fleet to strengthen the KN PharmaChain
Sep 05, 2018: Kuehne + Nagel (K+N) is investing in its European pharma fleet to strengthen the KN PharmaChain overland service in the region; thereby, the company is also well prepared for the peak season ahead. K+N has successfully deployed 35 new pharma trailers and before end of the year another 45 will be added to the existing fleet, with a further planned expansion of 200 trailers in the coming years.
By enlarging its own dedicated trailer fleet of standardised Schmitz Cargobull chassis with thermoking cooling units (mono, bi-temp and double-deck equipment), K+N aims at facilitating seamless services for active temperature-controlled FTL and LTL shipments across Europe. The overland pharma fleet is part of the KN PharmaChain network, providing multimodal GxP compliant door-to-door shipping on a global scale, enhanced visibility and traceability of the deliveries, as well as intensive and proactive risk management and integrated warehousing services.
Uwe Hott, senior VP Overland Europe at Kuehne + Nagel, “Logistics solutions for the pharma and healthcare industry are among the most important growth drivers for K+N’s overland and regional business. This investment is part of our commitment to provide comprehensive, GxP compliant transport solutions for the industry, which can be tailored to specific needs.”
The new pharma trailers are fully GxP compliant and offer state-of-the-art technology for temperature-controlled transports, including dual temperature, double-deck equipment, Transport Asset Protection Association (TAPA) compliant integrated security locks to be opened remotely with a unique code, integrated control panel, printer for temperature report and GPS control for positioning, temperature, door sensors, coupling and technical status.